Pathkey.AI swaps clinical trials for silicon dreams with Chipforge deal

Pathkey.AI has put a large new bet on the table, signing a binding share purchase agreement that gives it the right to acquire 100% of Singapore-based Chipforge Pte Ltd, an AI-driven semiconductor design and verification platform. For a company best known for TrialKey, its AI platform aimed at clinical trial optimisation, this is not so much a gentle sidestep as a brisk walk into one of technology’s hottest, hardest and most capital-hungry neighbourhoods.

The market context is useful. ASX data has Pathkey at $0.041 a share, with a market capitalisation of about $24.9 million, which makes the proposed paper-heavy acquisition highly material for existing shareholders.

What Chipforge brings to the bench

Chipforge is developing an agentic AI platform intended to translate high-level design intent into verified, synthesisable hardware code. In plainer English, the company wants engineers to describe what a chip should do, then have AI generate the hardware design, create verification tests and push the design towards implementation on FPGA hardware, with a roadmap towards full ASIC development.

That matters because custom chip development is notoriously slow and expensive. Pathkey says the process can take 12 to 24 months and cost millions of dollars, with verification alone often chewing through more than half of a chip project’s budget and timeline. Chipforge’s pitch is that AI agents can collapse part of this bottleneck, opening custom chip design to a wider market than the usual deep-pocketed semiconductor giants.

The target customer list is suitably fashionable: defence, aerospace, critical infrastructure, universities, research institutions and companies building custom chips for AI, edge computing and embedded systems. In the current market, any phrase involving AI, chips and sovereign capability tends to get investors’ ears twitching like a kelpie at dinner time.

The deal structure is big, even before milestones

The consideration is 560 million new Pathkey shares plus 150 million performance rights. The ordinary shares are struck at a deemed issue price of 2.2 cents, implying $12.32 million of headline scrip consideration before the performance rights and any market repricing.

On completion, Pathkey’s ordinary shares on issue would rise from 607.1 million to 1.167 billion. That means existing holders would move from owning all the company to about 52% of the enlarged ordinary share base, before the performance rights. If the 150 million rights eventually convert, the fully expanded base would move to about 1.317 billion shares, before considering existing options.

Those performance rights are not freebies, at least not on paper. Half vest on Pathkey demonstrating a minimum viable product using Chipforge intellectual property within nine months, subject to independent expert verification. The other half vest if the company signs at least one binding commercial agreement using the Chipforge IP with a credible customer that will deliver revenue within 12 months from the issue date of those rights.

The IP has university roots, and obligations

Chipforge’s core technology is licensed under an exclusive worldwide agreement with Ntuitive Pte Ltd, linked to Nanyang Technological University in Singapore. That licence is important because it underpins the commercial rights Pathkey is effectively chasing.

There are strings attached. Chipforge must raise at least S$1 million by 2 February 2027, achieve a first commercial sale by 2 February 2028 and generate cumulative net revenue of S$1 million by 2 February 2031 to retain exclusivity. Annual licence fees begin at S$20,000 and rise progressively to S$50,000 over a 16-year period.

Cash looks adequate, but not luxurious

Pathkey says it had about $3.26 million in cash at 31 March 2026 and expects about $840,000 in R&D rebates and other income over the next 12 months. The company does not currently expect to raise capital for the acquisition.

The proposed 12-month spend totals $4.1 million: $1.55 million for TrialKey, $1.5 million for Chipforge, $700,000 for working capital and corporate administration, and $350,000 for estimated transaction costs. That broadly matches cash plus expected receipts, so shareholders will be watching cash burn, rebate timing and whether early commercial traction arrives before the tin needs rattling again.

Management’s pitch

Pathkey chair Shannon Robinson framed the move as a strategic broadening of the company’s AI stack, saying the addition of “complementary AI chip-design technology” would materially strengthen its position. She also pointed to McKinsey’s forecast that the global semiconductor market could reach about US$1 trillion by 2030, driven by AI, data centres, edge computing, defence and next-generation workloads.

The logic is clear enough: TrialKey and Chipforge both rely on agent-based AI, large language model functionality and iterative optimisation. One applies it to clinical trial design. The other applies it to chip architecture, power, performance and silicon area.

The risk is equally clear. Pathkey is still an early-stage microcap, and semiconductor design is a brutal arena where proof-of-concept charm must eventually become robust, trusted and revenue-generating product. The next investor checkpoints are due diligence, shareholder approval, Ntuitive consent, completion before FY26 ends and, most importantly, whether Chipforge can turn the AI-chip-design story into working pilots and paying customers.